Medical AI stocks fell in overnight trading. Hims & Hers Health Inc. fell 19%; Tempus AI fell 14%.

Hims & Hers stock tumbled after the company released its Q4 earnings report and 2025 guidance amid a possible FDA crackdown on its GLP-1 weight-loss products.

On Friday, the FDA said that the semaglutide shortage has been resolved, a development that will likely force most compounded versions of the drug from the U.S. market. The agency said it would give compounders and distributors 60 days to transition, while outsourcing facilities will have 90 days.

In December, the FDA announced it had approved generic versions of the Novo Nordisk (NVO) GLP-1 drug liraglutide, also known as Victoza. The drug lost patent protection last year.

The agency said last week that liraglutide was still on its shortage list.

Palantir Technologies Inc. fell 3% in overnight trading. The technology and defense stock dropped about 10.5% on Monday, marking its fourth straight losing session and worst day since May. That comes after the stock fell 15% last week.

Zoom fell 3% in overnight trading after the videoconferencing company provided a disappointing first-quarter outlook.

Zoom said it expects first-quarter revenue to be between $1.16 billion and $1.17 billion, missing analysts’ consensus call for revenue of $1.18 billion, according to FactSet.